Designing, conducting and applying results from patient preference studies – The PREFER framework
- Date:
- Location: Online
- Lecturer: Conny Berlin (Novartis Pharma AG), Kristin Bullok (Eli Lilly and Companys), Brett Hauber (Pfizer), Bennett Levitan (Janssen Research & Development), Irina Cleemput (Belgian Health Care Knowledge Centre (KCE))
- Website
- Organiser: PREFER
- Contact person: Carl Steinbeisser
- Seminarium
This webinar will introduce the PREFER framework for patient preference studies, with a particular focus on points to consider for method selection and the application of preference study results to inform regulatory and HTA decision-making.
Incorporating patient preferences into decision-making is an important part of patient-focused drug development. The lack of a clear, practical framework for measuring patient preferences was one of stakeholders' main concerns brought up during PREFER’s initial research. In this webinar, we introduce the PREFER framework for patient preference studies.
Webinar agenda
Introduction to the PREFER framework & what we’d like this to achieve
Conny Berlin, IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology Novartis Pharma AG, Switzerland
How the PREFER framework addresses the study purpose; study organization, design & conduct
Kristin Bullok, Benefit-Risk Management Scientist, Global Patient Safety; Eli Lilly and Company, United States
Points to consider for method selection
Brett Hauber, Senior Director, Patient Preference Elicitation Pfizer, United States
PREFER framework continued: application of preference data to inform regulatory decision-making
Bennett Levitan, Senior Director, Benefit-Risk Assessment, Global R&D Epidemiology; Janssen Research & Development, United States
PREFER framework continued further: application of preference data to inform HTA decision-making
Irina Cleemput, Scientific Programme Director Belgian Health Care Knowledge Centre (KCE), Belgium
Q&A session
Chaired by Conny Berlin, IMI PREFER Project Leader & Global Head, Quantitative Safety and Epidemiology, Novartis Pharma AG, Switzerland